Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-000983
Filing Date
2025-02-14
Accepted
2025-02-14 09:02:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8645
2 JOINT FILING AGREEMENT p25-0294exhibit99_1.htm EX-99.1 3957
  Complete submission text file 0000902664-25-000983.txt   14342
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90685 | Film No.: 25623722
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607
Business Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G